0001415889-20-000755.txt : 20200316 0001415889-20-000755.hdr.sgml : 20200316 20200316161015 ACCESSION NUMBER: 0001415889-20-000755 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200315 FILED AS OF DATE: 20200316 DATE AS OF CHANGE: 20200316 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WEAVER GREGORY L CENTRAL INDEX KEY: 0001251779 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31326 FILM NUMBER: 20717228 MAIL ADDRESS: STREET 1: 185 BERRY STREET STREET 2: SUITE 6504 CITY: SAN FRANCISCO STATE: CA ZIP: 94107 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Eloxx Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001035354 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 841368850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 950 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (858) 909-0749 MAIL ADDRESS: STREET 1: 950 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Sevion Therapeutics, Inc. DATE OF NAME CHANGE: 20140930 FORMER COMPANY: FORMER CONFORMED NAME: SENESCO TECHNOLOGIES INC DATE OF NAME CHANGE: 19991006 FORMER COMPANY: FORMER CONFORMED NAME: NAVA LEISURE USA INC DATE OF NAME CHANGE: 19970310 4 1 form4-03162020_040301.xml X0306 4 2020-03-15 1 0001035354 Eloxx Pharmaceuticals, Inc. ELOX 0001251779 WEAVER GREGORY L C/O ELOXX PHARMACEUTICALS, INC. 950 WINTER STREET WALTHAM MA 02451 false false false true FORMER CHIEF FINANCIAL OFFICER Common Stock 2020-03-15 4 M 0 3750 0 A 11517 D Common Stock 2020-03-15 4 F 0 1086 2.85 D 10431 D Restricted Stock Units 2020-03-15 4 M 0 3750 0 D Common Stock 3750 0 D The restricted stock units issued to the reporting person on January 30, 2019 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. As a result of reporting person's separation from the Issuer, 25% of all unvested equity accelerated in accordance with the reporting person's employment agreement and the remaining unvested equity was forfeited. /s/ Neil S. Belloff, Attorney-in-Fact 2020-03-16